Texas Oncology-Baylor, Charles A. Sammons Cancer Center

Dallas, Texas 77380

18 studies enrolling now · 153 studies all time

What they study most

AML, AML With Mutated NPM1, Acinar Cell Carcinoma, Acute Leukemia, Acute Myeloid Leukemia, Adenocarcinoma, Adenocarcinoma, Papillary, Advanced Breast Cancer, Advanced Breast Cancer (Female), Advanced Breast Carcinoma, Advanced Cancer, Advanced Head and Neck Squamous Cell Carcinoma

Studies at this site

• A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting now
• Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors — Recruiting now
• A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors — Recruiting now
• Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects — Recruiting now
• A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer — Recruiting now
• A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors — Recruiting now
• Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells — Recruiting now
• A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer — Recruiting now
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting now
• A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies — Recruiting now
• First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors — Recruiting now
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer — Recruiting now
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
• Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. — Recruiting now
• Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease — Recruiting now
• JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors — Recruiting now
• MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles — Recruiting now
• A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. — Running, not enrolling
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma — Running, not enrolling
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study — Running, not enrolling
• A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure — Running, not enrolling
• Phase III Study of AK112 for NSCLC Patients — Running, not enrolling
• A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer — Running, not enrolling
• A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma — Running, not enrolling
• A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors — Stopped early
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer — Running, not enrolling
• A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) — Running, not enrolling
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma — Running, not enrolling
• Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer — Running, not enrolling
• Mirdametinib + BGB-3245 in Advanced Solid Tumors — Stopped early
• A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) — Running, not enrolling
• Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy — Completed
• MYLUNG Consortium Study Protocol 2 — Running, not enrolling
• Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma — Completed
• A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) — Running, not enrolling
• A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations — Completed
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release — Available (expanded access)
• A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment — Completed
• Dose Escalation and Dose Expansion Study of CPO-100 in Patients With Advanced Solid Tumors — Stopped early
• Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR) — Completed
• FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma — Completed
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) — Running, not enrolling
• Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) — Running, not enrolling
• A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Running, not enrolling
• A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors — Stopped early
• A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) — Running, not enrolling
• Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy — Completed
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers — Completed